Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02528305
Other study ID # 2015CM
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2015
Est. completion date June 2016

Study information

Verified date May 2018
Source University of Bath
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot study aims to investigate whether 6 weeks of twice weekly High-intensity Interval Training (HIT) results in improvements in disease-specific measures, feelings of general well-being, physical fitness and cognitive function in patients with non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.


Description:

The study aims to recruit up to 12 patients diagnosed with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) from the liver clinics at Ninewells Hospital, Dundee. Suitable patients who give informed consent will be assessed at baseline, again after 6 weeks of no intervention to act as a control period, and thirdly after 6 weeks of twice-weekly high-intensity interval training (HIT).

Assessments will be performed with the patient fasted overnight, and will involve body composition measurements, blood pressure, a venous blood sample for circulating triglycerides, fasting glucose, insulin, liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and platelets. An oral glucose tolerance test will be performed using fingerprick capillary samples. Cognitive function tests for episodic memory, executive function and semantic memory will be performed and a questionnaire (SF-36) will be used to assess general well-being. Physical fitness will be assessed through a 12-minute walk test on a treadmill, which will allow estimation of maximal oxygen uptake capacity (VO2 max), and a "get up and go" test will be used to assess physical function.

The exercise intervention will involve a 2 minute warm-up, cycling at 50 rpm before the participants will be asked to cycle at 100rpm and a weight will be added (7% body weight for men and 6% body weight for women) as resistance. The sprint will last 6 seconds and the participant will be asked to rest for at least 1 minute. This will be repeated for a total of 5 sprints in sessions 1-3, 6 sprints in session 4, 7 sprints in sessions 5&6, 8 sprints in sessions 7&8, 9 sprints in sessions 9&10 and 10 sprints in sessions 11&12. Exercise heart rate will be monitored and recorded.

At least 3 days after the last HIT session the pre-intervention testing assessment will be repeated for a third time.

Changes in measured variables will be analysed via repeated measures analysis of variance (ANOVA) with post-hoc testing of all variables.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date June 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender All
Age group 20 Years to 59 Years
Eligibility Inclusion Criteria:

- clinical diagnosis of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis

- attending a specialist liver clinic at Ninewells Hospital, Dundee

Exclusion Criteria:

- unstable cardiovascular disease

- uncontrolled arrhythmias

- structural cardiac abnormalities

- uncontrolled diabetes

- other uncontrolled metabolic abnormalities

- severe orthopaedic condition that would prohibit exercise

- severe pulmonary condition that would prohibit exercise

- any other poorly controlled medical condition.

- resting systolic blood pressure above 160 mm Hg

- resting diastolic blood pressure above 90 mm Hg

- symptomatic postural drop in blood pressure greater than 20 mm Hg

Study Design


Related Conditions & MeSH terms


Intervention

Other:
High-intensity Interval Training
2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5&6, 8 sprints in sessions 7&8, 9 sprints in sessions 9&10 and 10 sprints in sessions 11&12.

Locations

Country Name City State
United Kingdom Abertay University Dundee
United Kingdom Ninewells Hospital Dundee

Sponsors (2)

Lead Sponsor Collaborator
University of Bath Abertay University

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) calculation of insulin resistance via formula: fasting insulin (mIU/L) x fasting glucose (mg/dL)/405 normal insulin resistance -HOMA score <3 moderate insulin resistance -HOMA score 3-5 severe insulin resistance -HOMA score >5 Assessed at baseline, after 6 week control period and within 1 week of completing 6 weeks HIT Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Primary Oral Glucose Tolerance Test measurement of capillary samples for glucose at time 0, followed by every 20 minutes for 2 hours following ingestion of 75g glucose. Results graphed against time, then area under the curve calculated for each of the 3 assessments. Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Primary AST: ALT Ratio ratio of liver enzymes aspartate aminotransferase (AST) to alanine aminotransferase (ALT).
used as a diagnostic aid e.g. AST:ALT of more than 2:1 is characteristic of alcoholic liver disease whereas fatty steatosis and many other causes of liver disease, ratio is less than or equal to 1.
Ratio may rise as fibrosis and cirrhosis develop in viral hepatitis.
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Primary FIB-4 calculated from AST, ALT, platelets and participant's age and used to estimate amount of fibrosis in liver.
Fib-4 score of <1.45 has negative predictive value of 90% for advanced fibrosis.
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Primary Body Fat Mass Estimated Via Bioimpedance total body fat and trunk fat estimated via bioimpedance measured after overnight fast, expressed as percentage Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Primary Blood Pressure taken with participant supine, measured on left arm Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Primary General Well-being as Assessed by SF-36 Questionnaire Assessment of: physical functioning, social functioning, mental health, pain, change in health, physical role limitation, mental role limitation, energy and vitality, health perception over preceding 4 weeks (other than change in health, which is a comparison to health the preceding year), expressed as a transformed score range 0-100, with a higher score indicating better function/freedom from pain etc Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Primary Short-term Memory Recall testing of verbal word presentation-immediate recall of 10 words (60 seconds for recall) Maximum =10, minimum =0 Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Primary Estimated VO2 Max VO2 max estimated via submaximal exercise test-submaximal treadmill walking test Calculated via formula: VO2max= 15.1+21.8 x speed (miles per hour) - 0.327 x heart rate (beats per minute) - 0.263 x speed x age (years) + 0.00504 x heart rate x age + 5.98 x gender (0=female, 1=male) Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Primary Physical Function-"Get up and go" Test participant will be timed standing up from chair unaided,walking 30m, turning round and returning to a seated position on the chair, the average time of 3 attempts will be recorded. Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Primary Ankle Brachial Pressure Index (ABPI) ratio of blood pressure in left arm and right ankle Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Primary Long-term Memory Recall testing of verbal word presentation-delayed recall of 10 words 10 minutes after words initially presented (within 60 seconds).
Maximum= 10 words, minimum = no words
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Primary Executive Function (Verbal Fluency Test) written verbal fluency test: participant asked to write down as many English words as possible within 60 seconds, starting with a particular letter of the alphabet, excluding proper nouns or plurals.
Baseline assessment-letter A Post Control assessment -letter S After HIT assessment -letter F
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05480696 - Soluble Fibre Supplementation in NAFLD Phase 1
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Completed NCT04671186 - Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan N/A
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis Phase 2
Recruiting NCT05462353 - Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH Phase 2
Completed NCT05006885 - ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) Phase 1
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Recruiting NCT04365855 - The Olmsted NAFLD Epidemiology Study (TONES) N/A
Recruiting NCT05618626 - Prevention of NAFLD and CVD Through Lifestyle Intervention N/A
Completed NCT03256526 - 6-week Safety and PD Study in Adults With NAFLD Phase 2
Enrolling by invitation NCT06152991 - Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy Phase 3
Completed NCT03681457 - Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects Phase 1
Completed NCT06244550 - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors N/A
Not yet recruiting NCT05120557 - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH N/A
Completed NCT03060694 - Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
Completed NCT02526732 - Hepatic Inflammation and Physical Performance in Patients With NASH N/A
Recruiting NCT01988441 - The Influence of Autophagy on Fatty Liver
Recruiting NCT01680003 - Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease Phase 2
Completed NCT01712711 - Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease Phase 2
Recruiting NCT00941642 - Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Phase 4